Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Intercept Hopes Statin Trial Will Lessen Ocaliva's Perceived CV Risk

Mar 22 2017

• By Joseph Haas

Liver

Related Content

The NASH Pipeline: Replete With Targets And New Compounds

Aug 29 2016

Intercept Increases Chance Of Success In NASH Without Significant Delay

Feb 10 2017

Intercept rollercoaster continues with NASH, PBC updates

Nov 10 2014

Intercept’s NASH Phase III Enrolling Slowly; Gilead Could Gain Ground

Jan 13 2017

Intercept quiet on NASH safety data disclosure concerns

May 23 2014

Related Companies

Intercept Pharmaceuticals, Inc.

Pfizer Inc.

Genfit SA

Gilead Sciences, Inc.

Novo Nordisk A/S

Allergan plc

Additional Topics

Drug Safety Clinical Trials Research & Development Liver & Hepatic BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.